IRCT20200407046981N1尚未招募未知
Randomized, single-dose, crossover comparative bioequivalence study of Teriflunomide (Trigio®) 14 mg tablets produced by Zahravi Pharmaceutical Co. versus Aubagio® tablets of Sanofi Genzyme Co. in 14 healthy male under fasting conditions
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 years 至 60 years（—）
- 性别
- Male
入选标准
- •Healthy subjects with BMI 18.5-30 kg/m2
- •Not having any abnormal finding in laboratory examination or during physical examination.
- •Not having a history of any significant disease.
- •Subjects who agree with patient consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Ondansetron or any ingredients.
- •Subjects with BP = 9060 mm/Hg or BP = 140/90 mm/Hg Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function or a history of TB, epilepsy, asthma (during past 5 years), DM, psychosis or glaucoma.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two week before dosing
研究者
相似试验
招募中
不适用
Study of absorption and elimination rate of Erlotinib 150 mg tablets in comparison with standard tablet of Erlotinib (Tarceva).IRCT20200407046981N7Kimia pharmaceutical Co30
已完成
不适用
Bioequivalence study of Ondansetron 4 mg film-coated tablet in 24 healthy male under fasting conditionsIRCT20180620040164N2Aburaihan pharmaceutical co.24
已完成
不适用
bioequivalence study of Escitalopram 10 mg film-coated tablets in 18 healthy male under fasting conditionsIRCT20180620040164N5Actover pharmaceutical co.18
招募中
不适用
Study of absorption and elimination rate of Imatinib 100 mg capsules in comparison with standard tablet of Imatinib (Imatinib).IRCT20200407046981N4Kimia pharmaceutical Co18
已完成
不适用
Bioequivalence study of Linagliptin 5 mg tablets in 24 healthy male under fasting conditionsIRCT20180620040164N4Alhavi pharmaceutical co.24